Business Description
Sight Sciences Inc
NAICS : 423450
SIC : 5047
ISIN : US82657M1053
Total Employee Number:
186Description
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.9 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.79 | |||||
Debt-to-EBITDA | -1.73 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.73 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.2 | |||||
3-Year EBITDA Growth Rate | 28.1 | |||||
3-Year EPS without NRI Growth Rate | 23.2 | |||||
3-Year FCF Growth Rate | 29.1 | |||||
3-Year Book Growth Rate | -28.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.87 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.23 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.51 | |||||
9-Day RSI | 50.34 | |||||
14-Day RSI | 59.08 | |||||
3-1 Month Momentum % | 61.34 | |||||
6-1 Month Momentum % | 101.35 | |||||
12-1 Month Momentum % | 102.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.95 | |||||
Quick Ratio | 4.67 | |||||
Cash Ratio | 3.89 | |||||
Days Inventory | 252.06 | |||||
Days Sales Outstanding | 44.73 | |||||
Days Payable | 62.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | -0.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.96 | |||||
Operating Margin % | -33.43 | |||||
Net Margin % | -35.69 | |||||
EBITDA Margin % | -29.06 | |||||
FCF Margin % | -27.97 | |||||
OCF Margin % | -27.87 | |||||
ROE % | -48.78 | |||||
ROA % | -26.19 | |||||
ROIC % | -161.46 | |||||
3-Year ROIIC % | 21894.86 | |||||
ROC (Joel Greenblatt) % | -212.45 | |||||
ROCE % | -24.9 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.18 | |||||
PB Ratio | 8.31 | |||||
Price-to-Tangible-Book | 8.31 | |||||
EV-to-EBIT | -16.49 | |||||
EV-to-EBITDA | -16.77 | |||||
EV-to-Revenue | 4.87 | |||||
EV-to-Forward-Revenue | 1.81 | |||||
EV-to-FCF | -17.42 | |||||
Price-to-GF-Value | 1.73 | |||||
| Price-to-Net-Current-Asset-Value | 8.96 | |||||
| Price-to-Net-Cash | 15.8 | |||||
Earnings Yield (Greenblatt) % | -6.06 | |||||
FCF Yield % | -5.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SGHT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sight Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 83.377 | ||
| EPS (TTM) ($) | -0.56 | ||
| Beta | 4.3747 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 1.06 | ||
| Volatility % | 110.99 | ||
| 14-Day RSI | 59.08 | ||
| 14-Day ATR ($) | 0.405624 | ||
| 20-Day SMA ($) | 8.29 | ||
| 12-1 Month Momentum % | 102.44 | ||
| 52-Week Range ($) | 3.19 - 9.2362 | ||
| Shares Outstanding (Mil) | 55.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sight Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sight Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-04 16:30 | In 177 days | ||
| Annual report for 2026 | 2027-03-04 | In 176 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-04 | In 176 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 59 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 58 days | ||
| Morgan Stanley Global Healthcare Conference | 2026-09-15 09:15 | In 7 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 5.64 (+1.99%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 5.64 (+1.99%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 4.34 (+0.23%) | ||
| Guidance call for 2026 | 2026-05-26 12:00 | 5.03 (-3.08%) |
Show
Entries
Sight Sciences Inc Frequently Asked Questions
What is Sight Sciences Inc(SGHT)'s stock price today?
The current price of SGHT is $8.06. The 52 week high of SGHT is $9.24 and 52 week low is $3.19.
When is next earnings date of Sight Sciences Inc(SGHT)?
The next earnings date of Sight Sciences Inc(SGHT) is 2026-11-06 Est..
Does Sight Sciences Inc(SGHT) pay dividends? If so, how much?
Sight Sciences Inc(SGHT) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry | 2023-01-04 |
Articles on Sight Sciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers